Expression of mitotic checkpoint proteins BUB1B and MAD2L1 in salivary duct carcinomas

Journal of Oral Pathology and Medicine

Volumn 39, Issue 4, 2010, Pages 349-355

  Ko, Young Hyeh ^a   Roh, Ji Hyeon ^a   Son, Young Ik ^a   Chung, Man Ki ^a   Jang, Jeon Yeob ^a   Byun, Hayoung ^a   Baek, Chung Hwan ^a   Jeong, Han Sin ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

BUB1B; MAD2L1; Prognosis; Salivary duct carcinomas; Salivary gland neoplasm

Indexed keywords

ANDROGEN RECEPTOR; BENZIMIDAZOLE 1 HOMOLOG BETA PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOSIS ARREST DEFICIENT 2 LIKE 1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SALIVARY GLAND CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CALCIUM-BINDING PROTEINS; CARCINOMA; CELL CYCLE PROTEINS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; REMISSION INDUCTION; REPRESSOR PROTEINS; SALIVARY DUCTS; SALIVARY GLAND NEOPLASMS; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77950478328     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2009.00835.x     Document Type: Article

References (43)

1. Barnes L, Rao U, Contis L, Krause J, Schwartz A, Scalamogna P. Salivary duct carcinoma Part II. Immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D, and c-erbB-2 protein. Oral Surg Oral Med Oral Pathol 1994 78 : 74 80.
2. Barnes L, Rao U, Krause J, Contis L, Schwartz A, Scalamogna P. Salivary duct carcinoma Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol 1994 78 : 64 73.
3. Delgado R, Vuitch F, Albores-Saavedra J. Salivary duct carcinoma. Cancer 1993 72 : 1503 1512.
4. Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol 2000 24 : 579 586.
5. Hellquist HB, Karlsson MG, Nilsson C. Salivary duct carcinoma - a highly aggressive salivary gland tumour with overexpression of c-erbB-2. J Pathol 1994 172 : 35 44.
6. Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD. Salivary duct carcinoma clinicopathologic and immunohistochemical review of 26 cases. Cancer 1996 77 : 223 230.
7. Simpson RH, Clarke TJ, Sarsfield PT, Babajews AV. Salivary duct adenocarcinoma. Histopathology 1991 18 : 229 235.
8. Brandwein MS, Jagirdar J, Patil J, Biller H, Kaneko M. Salivary duct carcinoma (cribriform salivary carcinoma of excretory ducts). A clinicopathologic and immunohistochemical study of 12 cases. Cancer 1990 65 : 2307 2314.
9. Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Loning T. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 2005 103 : 2526 2533.
10. Brandwein-Gensler M, Hille J, Wang BY, et al. Low-grade salivary duct carcinoma: description of 16 cases. Am J Surg Pathol 2004 28 : 1040 1044.
11. Etges A, Pinto DS Jr., Kowalski LP, Soares FA, Araujo VC. Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. J Clin Pathol 2003 56 : 914 918.
12. Moriki T, Ueta S, Takahashi T, Mitani M, Ichien M. Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer 2001 93 : 344 350.
13. Nasser SM, Faquin WC, Dayal Y. Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am J Clin Pathol 2003 119 : 801 806.
14. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005 5 : 773 785.
15. Logarinho E, Bousbaa H. Kinetochore-microtubule interactions "in check" by Bub1, Bub3 and BubR1: the dual task of attaching and signalling. Cell Cycle 2008 7 : 1763 1768.
16. Coleman SC, Stewart ZA, Day TA, Netterville JL, Burkey BB, Pietenpol JA. Analysis of cell-cycle checkpoint pathways in head and neck cancer cell lines: implications for therapeutic strategies. Arch Otolaryngol Head Neck Surg 2002 128 : 167 176.
17. Cheung HW, Chun AC, Wang Q, et al. Inactivation of human MAD2B in nasopharyngeal carcinoma cells leads to chemosensitization to DNA-damaging agents. Cancer Res 2006 66 : 4357 4367.
18. Cheung HW, Jin DY, Ling MT, et al. Mitotic arrest deficient 2 expression induces chemosensitization to a DNA-damaging agent, cisplatin, in nasopharyngeal carcinoma cells. Cancer Res 2005 65 : 1450 1458.
19. Wang X, Jin DY, Wong HL, Feng H, Wong YC, Tsao SW. MAD2-induced sensitization to vincristine is associated with mitotic arrest and Raf/Bcl-2 phosphorylation in nasopharyngeal carcinoma cells. Oncogene 2003 22 : 109 116.
20. Wang X, Jin DY, Wong YC, et al. Correlation of defective mitotic checkpoint with aberrantly reduced expression of MAD2 protein in nasopharyngeal carcinoma cells. Carcinogenesis 2000 21 : 2293 2297.
21. Thirthagiri E, Robinson CM, Huntley S, et al. Spindle assembly checkpoint and centrosome abnormalities in oral cancer. Cancer Lett 2007 258 : 276 285.
22. Mondal G, Sengupta S, Panda CK, Gollin SM, Saunders WS, Roychoudhury S. Overexpression of Cdc20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis 2007 28 : 81 92.
23. Minhas KM, Singh B, Jiang WW, Sidransky D, Califano JA. Spindle assembly checkpoint defects and chromosomal instability in head and neck squamous cell carcinoma. Int J Cancer 2003 107 : 46 52.
24. Burum-Auensen E, De Angelis PM, Schjolberg AR, Kravik KL, Aure M, Clausen OP. Subcellular localization of the spindle proteins Aurora A, Mad2 and BUBR1 assessed by immunohistochemistry. J Histochem Cytochem 2007 55 : 477 486. (Pubitemid 46668629)
25. Hanks S, Coleman K, Reid S, et al. Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUBR1. Nat Genet 2004 36 : 1159 1161. (Pubitemid 41288963)
26. Li GQ, Li H, Zhang HF. MAD2 and p53 expression profiles in colorectal cancer and its clinical significance. World J Gastroenterol 2003 9 : 1972 1975. (Pubitemid 37168424)
27. Shichiri M, Yoshinaga K, Hisatomi H, Sugihara K, Hirata Y. Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. Cancer Res 2002 62 : 13 7. (Pubitemid 34073977)
28. Tanaka K, Nishioka J, Kato K, et al. Mitotic checkpoint protein hsMAD2 as a marker predicting liver metastasis of human gastric cancers. Jpn J Cancer Res 2001 92 : 952 958. (Pubitemid 32970436)
29. Felix A, El-Naggar AK, Press MF, et al. Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol 1996 27 : 561 566. (Pubitemid 26187279)
30. Grenko RT, Gemryd P, Tytor M, Lundqvist PG, Boeryd B. Salivary duct carcinoma. Histopathology 1995 26 : 261 266.
31. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual, 6th edn.
32. Hosal AS, Fan C, Barnes L, Myers EN. Salivary duct carcinoma. Otolaryngol Head Neck Surg 2003 129 : 720 725. (Pubitemid 37509773)
33. Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 2003 39 : 724 727. (Pubitemid 36930120)
34. Lim JJ, Kang S, Lee MR, et al. Expression of vascular endothelial growth factor in salivary gland carcinomas and its relation to p53, Ki-67 and prognosis. J Oral Pathol Med 2003 32 : 552 561. (Pubitemid 37175008)
35. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science 1996 274 : 1664 1672.
36. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998 396 : 643 649. (Pubitemid 29003936)
37. Grabsch H, Takeno S, Parsons WJ, et al. Overexpression of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in gastric cancer-association with tumour cell proliferation. J Pathol 2003 200 : 16 22. (Pubitemid 36592631)
38. Cahill DP, Lengauer C, Yu J, et al. Mutations of mitotic checkpoint genes in human cancers. Nature 1998 392 : 300 303. (Pubitemid 28155105)
39. Gemma A, Seike M, Seike Y, et al. Somatic mutation of the hBUB1 mitotic checkpoint gene in primary lung cancer. Genes Chromosomes Cancer 2000 29 : 213 218.
40. Nomoto S, Haruki N, Takahashi T, et al. Search for in vivo somatic mutations in the mitotic checkpoint gene, hMAD1, in human lung cancers. Oncogene 1999 18 : 7180 7183. (Pubitemid 30028890)
41. Li GQ, Zhang HF. Mad2 and p27 expression profiles in colorectal cancer and its clinical significance. World J Gastroenterol 2004 10 : 3218 3220. (Pubitemid 39419895)
42. Pati D, Haddad BR, Haegele A, et al. Hormone-induced chromosomal instability in p53-null mammary epithelium. Cancer Res 2004 64 : 5608 5616. (Pubitemid 39095556)
43. Shin HJ, Baek KH, Jeon AH, et al. Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability. Cancer Cell 2003 4 : 483 497.